|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 1001 Pennsylvania Avenue NW |
Address2 | Suite 710 |
City | Washington |
State | DC |
Zip Code | 20004 |
Country | USA |
3. Principal place of business (if different than line 2)
City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 6484-12
|
||||||||
|
6. House ID# 314020000
|
TYPE OF REPORT | 8. Year | 2022 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Samuel Marchio |
Date | 7/20/2022 4:48:45 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
ACA implementation (exchange operations and functionality, risk mitigation programs, risk adjustment)
ACA reform (individual mandate, cost sharing reduction subsidies, reinsurance transitional policies) ACA 1332 Waivers
Individual market and exchange stabilization
Prior authorization
Hospital Consolidation
Transparency of Hospital Billing Act (H.R.8133)
Privacy and Healthcare Cybersecurity
Social Determinants of Health (SDOH)
Mental health and substance use, Parity and compliance issues.
Restoring Hope for Mental Health and Well-Being Act of 2022 (H.R.7666)
Behavioral Health Crisis Intervention and 9-8-8 hotline services
Mental health parity and MHPAEA compliance
Surprise medical billing;
Price of prescription drugs
Pharmacy Benefit Manager (PBM) operations and practices, Spread pricing,
Pharmacy Benefit Manager Transparency Act (S. 4293)
Chronic Kidney Disease Conditions of Coverage Reform
COVID-19 testing, vaccines, treatment, cost sharing
Medicare Sequestration, ACA subsidies, COVID vaccines and testing, Consolidated Appropriations Act
Behavioral Health
Telehealth
Short Term Limited Duration health plans
Consolidated Appropriations Act (H.R. 133)
Medical Loss Ratio; To amend title XXVII of the Public Health Service Act to include activities to address social determinants of health in the calculation of medical loss ratios (H.R. 3969)
Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act
Federal Medical Assistance Percentages (FMAP) increase
Special Enrollment Period
CONNECT for Health Act
Hospital Claims Form Issues
Build Back Better Act (H.R.5376)
KEEP Telehealth Options Act
Agent/broker compensation disclosures under the Consolidated Appropriations Act.
CAA regulation implementation
Hospital Competition Act
Medicaid eligibility
Health Equity/Health Disparities
Postal Service Reform Act of 2022
Defense Health Programs (FY2022 Budget and FY2023 Budget Request)
Veterans Health Care (U.S. Department of Veterans Affairs Assets and Infrastructure Review Report)
2018 MISSION Act
Veterans PACT Act
Achieving Equity in the Treatment of Dual Eligible Beneficiaries Act (H.R. 7997)
Bipartisan Safer Communities Act
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Treasury - Dept of, Labor - Dept of (DOL), Agency for Healthcare Research & Quality (AHRQ)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Samuel |
Marchio |
|
|
|
Adam |
Goldberg |
|
|
|
Catherine |
Nabavi |
|
|
|
James |
Stursberg |
|
|
|
Elizabeth |
Hall |
|
|
|
Timothy |
Drumm |
|
|
|
Simone |
Myrie |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code INS
16. Specific lobbying issues
ACA implementation (exchange operations and functionality, risk mitigation programs, risk adjustment)
ACA reform (individual mandate, cost sharing reduction subsidies, reinsurance transitional policies) ACA 1332 Waivers
Individual market and exchange stabilization
Prior authorization
Hospital Consolidation
Transparency of Hospital Billing Act (H.R.8133)
Privacy and Healthcare Cybersecurity
Social Determinants of Health (SDOH)
Mental health and substance use, Parity and compliance issues.
Restoring Hope for Mental Health and Well-Being Act of 2022 (H.R.7666)
Behavioral Health Crisis Intervention and 9-8-8 hotline services
Mental health parity and MHPAEA compliance
Surprise medical billing;
Price of prescription drugs
Pharmacy Benefit Manager (PBM) operations and practices, Spread pricing,
Pharmacy Benefit Manager Transparency Act (S. 4293)
Chronic Kidney Disease Conditions of Coverage Reform
COVID-19 testing, vaccines, treatment, cost sharing
Medicare Sequestration, ACA subsidies, COVID vaccines and testing, Consolidated Appropriations Act
Behavioral Health
Telehealth
Short Term Limited Duration health plans
Consolidated Appropriations Act (H.R. 133)
Medical Loss Ratio; To amend title XXVII of the Public Health Service Act to include activities to address social determinants of health in the calculation of medical loss ratios (H.R. 3969)
Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act
Federal Medical Assistance Percentages (FMAP) increase
Special Enrollment Period
CONNECT for Health Act
Hospital Claims Form Issues
Build Back Better Act (H.R.5376)
KEEP Telehealth Options Act
Agent/broker compensation disclosures under the Consolidated Appropriations Act.
CAA regulation implementation
Hospital Competition Act
Medicaid eligibility
Health Equity/Health Disparities
Postal Service Reform Act of 2022
Defense Health Programs (FY2022 Budget and FY2023 Budget Request)
Veterans Health Care (U.S. Department of Veterans Affairs Assets and Infrastructure Review Report)
2018 MISSION Act
Veterans PACT Act
Achieving Equity in the Treatment of Dual Eligible Beneficiaries Act (H.R. 7997)
Bipartisan Safer Communities Act
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Treasury - Dept of, Labor - Dept of (DOL), Agency for Healthcare Research & Quality (AHRQ)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Samuel |
Marchio |
|
|
|
Adam |
Goldberg |
|
|
|
Catherine |
Nabavi |
|
|
|
James |
Stursberg |
|
|
|
Elizabeth |
Hall |
|
|
|
Timothy |
Drumm |
|
|
|
Simone |
Myrie |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
ACA implementation (exchange operations and functionality, risk mitigation programs, risk adjustment)
ACA reform (individual mandate, cost sharing reduction subsidies, reinsurance transitional policies) ACA 1332 Waivers
Individual market and exchange stabilization
Prior authorization
Hospital Consolidation
Transparency of Hospital Billing Act (H.R.8133)
Privacy and Healthcare Cybersecurity
Social Determinants of Health (SDOH)
Mental health and substance use, Parity and compliance issues.
Restoring Hope for Mental Health and Well-Being Act of 2022 (H.R.7666)
Behavioral Health Crisis Intervention and 9-8-8 hotline services
Mental health parity and MHPAEA compliance
Surprise medical billing;
Price of prescription drugs
Pharmacy Benefit Manager (PBM) operations and practices, Spread pricing,
Pharmacy Benefit Manager Transparency Act (S. 4293)
Chronic Kidney Disease Conditions of Coverage Reform
COVID-19 testing, vaccines, treatment, cost sharing
Medicare Sequestration, ACA subsidies, COVID vaccines and testing, Consolidated Appropriations Act
Behavioral Health
Telehealth
Short Term Limited Duration health plans
Consolidated Appropriations Act (H.R. 133)
Medical Loss Ratio; To amend title XXVII of the Public Health Service Act to include activities to address social determinants of health in the calculation of medical loss ratios (H.R. 3969)
Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act
Federal Medical Assistance Percentages (FMAP) increase
Special Enrollment Period
CONNECT for Health Act
Hospital Claims Form Issues
Build Back Better Act (H.R.5376)
KEEP Telehealth Options Act
Agent/broker compensation disclosures under the Consolidated Appropriations Act.
CAA regulation implementation
Hospital Competition Act
Medicaid eligibility
Health Equity/Health Disparities
Postal Service Reform Act of 2022
Defense Health Programs (FY2022 Budget and FY2023 Budget Request)
Veterans Health Care (U.S. Department of Veterans Affairs Assets and Infrastructure Review Report)
2018 MISSION Act
Veterans PACT Act
Achieving Equity in the Treatment of Dual Eligible Beneficiaries Act (H.R. 7997)
Bipartisan Safer Communities Act
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Treasury - Dept of, Labor - Dept of (DOL), Agency for Healthcare Research & Quality (AHRQ)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Samuel |
Marchio |
|
|
|
Adam |
Goldberg |
|
|
|
Catherine |
Nabavi |
|
|
|
James |
Stursberg |
|
|
|
Jonathan |
Bonet-Rivera |
|
|
|
Elizabeth |
Hall |
|
|
|
Timothy |
Drumm |
|
|
|
Simone |
Myrie |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
Price of prescription drugs; antitrust issues; Prescription Drug Pricing Reduction Act
Pharmacy Benefit Manager (PBM) operations and practices, Spread pricing,
Drug Rebate Rule/Executive Order
Senate Finance Committee Prescription Drug Pricing Reduction Act
Lower Drug Costs Now Act (H.R. 3)
Drug Patent Reform
Robinson-Patman Reform
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Treasury - Dept of, Labor - Dept of (DOL), Agency for Healthcare Research & Quality (AHRQ)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Samuel |
Marchio |
|
|
|
Catherine |
Nabavi |
|
|
|
James |
Stursberg |
|
|
|
Adam |
Goldberg |
|
|
|
Elizabeth |
Hall |
|
|
|
Timothy |
Drumm |
|
|
|
Simone |
Myrie |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code FIN
16. Specific lobbying issues
Federal Medical Assistance Percentages (FMAP) increase
COVID-19 testing, vaccinations, cost sharing for COVID-19 testing
APTC Expansion and Permanency
CARES Act
Blockchain
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Treasury - Dept of, Labor - Dept of (DOL), Agency for Healthcare Research & Quality (AHRQ)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Samuel |
Marchio |
|
|
|
Adam |
Goldberg |
|
|
|
Catherine |
Nabavi |
|
|
|
James |
Stursberg |
|
|
|
Elizabeth |
Hall |
|
|
|
Timothy |
Drumm |
|
|
|
Simone |
Myrie |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
Lobbyist Name | Description of Offense(s) |